SCHEMBL22561413

SCHEMBL22561413

CC#CCCCC(=O)NC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.41
MCL1 Q07820 2/20 0.37
EPHX2 P34913 1/20 0.37
SELP P16109 1/20 0.34
PTPN7 P35236 5/20 0.33
POLB P06746 2/20 0.33
RECQL P46063 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22040693 0.83 HDAC3 (0.52) CYP1A2CYP2C9SMN1; SMN2NPC1RAB9A
SCHEMBL22561261 0.79 FAAH (0.53) CYP1A2CYP2C9SMN1; SMN2NPC1RAB9A
SCHEMBL3080727 0.77
SCHEMBL29016761 0.77 HDAC3 (0.56) CYP1A2CYP2C9SMN1; SMN2NPC1RAB9A
SCHEMBL3084079 0.76
SCHEMBL7753090 0.75 LMNA (0.57) SMN1; SMN2KDM4ELMNAMCL1POLB
SCHEMBL5909180 0.75 LMNA (0.57) KDM4ELMNAMCL1POLBRECQL
SCHEMBL21137680 0.75 HPGD (0.47) CYP1A2CYP2C9SMN1; SMN2NPC1RAB9A
SCHEMBL17446915 0.75
SCHEMBL576308 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357259-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-11-09 US disclosed
EP-3725798-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2020-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357259-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF DOCK11, PAICS, RHOA CYP1A2 3650/4885CYP2C9 4293/4885SMN1; SMN2 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.